Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
1	19/WM/0056	256301	Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease	Range Agreed	50	113	Date Agreed	30/08/2021	112	112	27/02/2021	Recruitment finished	
2	19/SC/0034	254823	A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.	Range Agreed	3	6	Date Agreed	10/02/2021	2	2	10/02/2021	Withdrawn by sponsor	Recruitment ended early nationally
3	18/SW/0199	249896	Screening Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE)	Number Agreed	1	1	Date Agreed	30/06/2025	1	1	26/02/2021	Recruitment finished	
4	19/EM/0072	256161	A Long-Term, Randomized, Double-Blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as needed in Response to Symptoms in Symptomatic Adults and Children 4 years of Age or Older with Asthma (MANDALA)	Range Agreed	2	4	Date Agreed	30/01/2021	3	3	30/01/2021	Recruitment finished	
5	19/LO/0357	258769	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy.	Number Agreed	4	4	Date Agreed	31/03/2021	0	0	26/03/2021	Withdrawn by PI	Chronic understaffing due to COVID meant the team were unable to find recruits for the study. The PI took the decision that it wasn't currently safe to continue with the study
6	19/NW/0716	273613	A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects	Range Agreed	1	5	Date Agreed	10/08/2021	5	5	08/02/2021	Recruitment finished	
7	20/YH/0090	278137	AN OPEN-LABEL,MULTICENTER, ROLLOVER STUDYTO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OFGANTENERUMABIN PARTICIPANTSWITHALZHEIMER'S DISEASE	Number Agreed	1	1	Date Agreed	31/10/2022	1	1	31/03/2021	Recruitment finished	
8	20/YH/0231	284781	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA	Number Agreed	2	2	Date Agreed	15/06/2021	2	2	28/02/2021	Recruitment finished	
9	20/HRA/4325	288451	A retrospective study of the characteristics and outcomes of patients with familial chylomicronaemia syndrome treated with volanesorsen in the United Kingdom early access to medicines scheme	Range Agreed	1	2	Date Agreed	11/01/2021	1	1	11/01/2021	Recruitment finished	
10	20/EM/0142	282923	Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear)	Number Agreed	1	1	Date Agreed	27/08/2021	1	1	31/03/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
11	20/LO/0461	279984	Real-World Anti-VEGF Treatment Experience Study of the Management of Neovascular Age-Related Macular Degeneration in the UK (RATE Study in nAMD)	Range Agreed	15	20	Date Agreed	31/01/2021	17	17	31/01/2021	Recruitment finished	
12	19/YH/0301	268446.00	A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation	Range Agreed	2	4	Date Agreed	31/03/2021	0	0	22/03/2021	Withdrawn by sponsor	M19-530 study is now closed in the UK and Ethics has been notified of Permanent closure. Abbvie will now begin close out activities for all sites that had a finalised contract in place.
13	20/HRA/5205	289098	A PHASE I/II RANDOMIZED, TWO PARTS, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF AN INACTIVATED, ADJUVANTED SARS-COV-2 VIRUS VACCINE CANDIDATE (VLA2001), AGAINST COVID-19 IN HEALTHY INDIVIDUALS	Number Agreed	35	35	Date Agreed	15/01/2021	37	37	15/01/2021	Recruitment finished	
14	19/LO/1986	273932	AMD Barometer - Investigating patient-driven barriers to long-term anti-VEGF treatment adherence in wet AMD.	Number Agreed	9	9	Date Agreed	28/02/2021	9	9	28/02/2021	Recruitment finished	
15	18/LO/1923	253458	A descriptive non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke attributable to nonvalvular atrial fibrillation	Range Agreed	40	50	Date Agreed	30/06/2021	43	43	30/06/2021	Recruitment finished	
16	19/NE/0260	265062	An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy	Number Agreed	5	5	Date Agreed	07/06/2021	5	5	30/04/2021	Recruitment finished	
17	19/EM/0111	262811	CRTH258C2302: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (RAVEN)	Number Agreed	4	4	Date Agreed	16/07/2021	4	4	27/05/2021	Recruitment finished	
18	19/NE/0247	259906	A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction	Range Agreed	5	10	Date Agreed	30/06/2021	4	4	30/06/2021	Recruitment finished	Study recruitment was impacted by COVID-19 and the study team was unable to meet the target of 5
19	19/NE/0269	268944	A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)	Number Agreed	3	3	Date Agreed	44260	3	3	44246	Recruitment finished	
20	19/SC/0209	263492	A multinational, multicentre, prospective non-interventional study to assess safety and effectiveness of opicapone plus standard of care in elderly patients with Parkinson's Disease	Range Agreed	2	6	Date Agreed	28/04/2021	2	2	22/04/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
21	20/NE/0032	273692	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER	Range Agreed	2	5	Date Agreed	31/03/2021	0	0	44266	Recruitment finished	The team failed to recruit any patients. Due to coronavirus the patients were presenting with more advanced disease and poorer performance status than would be eligible for the study
22	20/SC/0031	275229	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis	Range Agreed	1	3	Date Agreed	30/06/2021	0	0	22/04/2021	Withdrawn by sponsor	Global recruitment ended prior to staff capacity issues being resolved at local site
23	20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting	Range Agreed	1	10	Date Agreed	44293	0	0	07/04/2021	Withdrawn by sponsor	After careful consideration, Gilead (Sponsor) made the decision to stop enrollment in study GS-US-540-9012. In light of recent advances, the primary unmet need for patients outside of the hospital setting is for convenient, effective therapies that can be easily administered at home.
24	20/NW/0177	1003027	Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205.	Range Agreed	1	2	Date Agreed	30/04/2021	1	1	30/04/2021	Recruitment finished	
25	20/WA/0203	281292	POLARx Cardiac Cryoablation system Post Market Clinical Follow-up study	Range Agreed	1	10	Date Agreed	30/06/2021	10	10	44342	Recruitment finished	
26	20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Number Agreed	200	200	Date Agreed	09/04/2021	207	207	09/04/2021	Recruitment finished	
27	21/NW/0125	294164	A RANDOMIZED, OBSERVER-BLIND, CONTROLLED, SUPERIORITY STUDY TO COMPARE THE IMMUNOGENICITY AGAINST COVID-19, OF VLA2001 VACCINE TO AZD1222 VACCINE, IN ADULTS	Range Agreed	120	200	Date Agreed	03/06/2021	134	134	03/06/2021	Recruitment finished	
28	19/LO/1753	269460	A phase 2, randomised, double-blind, placebo controlled study to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of SAR339375 for subutaneous injection administered every week in patients with Alport Syndrome	Number Agreed	1	1	Date Agreed	44347	2	2	31/05/2021	Recruitment finished	
29	18/WM/0038	235048	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy.	Number Agreed	1	1	Date Agreed	44358	0	0	11/06/2021	Recruitment finished	Recruitment closed globally. However, study was very difficult to recruit to due to standard medication being already available

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
30	18/SW/0159	244565	An International, Prospective Registry Investigating the Natural History of Children with Achondroplasia	Range Agreed	5	10	Date Agreed	30/06/2023	5	5	09/08/2021	Recruitment finished	
31	18/SC/0305	246109	A randomized, open-label, phase II open platform study evaluting the efficacy and safety of novel Spartalizumab (PDR001) combinations in previously treated unresected or metastatic melanoma	Range Agreed	5	12	Date Agreed	05/07/2021	0	0	26/05/2021	Withdrawn by sponsor	Sponsor closed all arms of this study
32	17/EM/0192	223856	A Phase 2, 24-week, Randomized, Double-Blind, Placebo-Controlled, Mulitcenter Study, Followed by a 24-Week Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis	Range Agreed	1	3	Date Agreed	44530	3	3	23/07/2021	Recruitment finished	
33	19/NM/0442	262204	An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis	Number Agreed	2	2	Date Agreed	30/06/2021	2	2	30/06/2021	Recruitment finished	
34	18/LO/1937	249639	A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors	Range Agreed	1	3	Date Agreed	30/09/2021	2	2	10/06/2021	Recruitment finished	
35	19/EM/0300	267054	Effectiveness of an image analysing algorithm to diagnose non-melanoma skin cancers compared to gold standard histological determination.	Range Agreed	10	50	Date Agreed	30/07/2021	10	10	30/07/2021	Recruitment finished	
36	20/EE/0031	275993	Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke	Range Agreed	8	10	Date Agreed	44410	7	7	44399	Recruitment finished	Global target was hit earlier than expected and the sponsor closed the study to recruitment
37	20/NI/0111	283403	AT100-01: An AAV8 Neutralizing Antibody Seroprevalence Study in Subjects with Late Onset Pompe Disease	Number Agreed	5	5	Date Agreed	01/07/2021	5	5	01/07/2021	Recruitment finished	
38	20/EE/0170	1003070	Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction	Number Agreed	10	10	Date Agreed	31/07/2021	7	7	15/07/2021	Recruitment finished	Recruitment ended early nationally after global recruitment was met
39	20/LO/0828	279777	Master protocol of two randomized, double-blind, placebo controlled, multi center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment in patients naïve to omalizumab and in patients who are intolerant or incomplete responders to omalizumab	Number Agreed	1	1	Date Agreed	44496	0	0	44469	Withdrawn by sponsor	Due to the pandemic, the UK recruitment was sinigicantly affected and sponsor closed the study earlier than expected

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
40	20/YH/0178	283168	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.	Number Agreed	4	4	Date Agreed	31/10/2021	0	0	03/09/2021	Withdrawn by sponsor	Recruitment finished early nationally
41	20/EM/0284	288568	A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chronic Hepatitis B Virus (B-Together)	Range Agreed	1	2	Date Agreed	31/10/2021	1	1	25/08/2021	Recruitment finished	
42	21/SC/0200	300677	A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults Ages 30 and Above to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2	Range Agreed	50	70	Date Agreed	07/09/2021	62	62	07/09/2021	Recruitment finished	
43	19/SW/0191	270987	Ross for Valve replacement in Adults(REVIVAL) Registry	Range Agreed	6	18	Date Agreed	31/07/2022	5	5	04/10/2021	Withdrawn by sponsor	Due to issues with recruitment and lack of demonstrable feasibility for the main trial, the sponsor came to the decision to close recruitment earlier than expected
44	18/WM/0039	236159	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433	Number Agreed	1	1	Date Agreed	01/01/2022	0	0	15/09/2021	Withdrawn by sponsor	No patients were found suitable to proceed to the extension study, which was closed by sponsor
45	18/LO/1125	247338	Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen	Range Agreed	3	8	Date Agreed	44519	6	6	44519	Recruitment finished	
46	17/NE/0058	219540	A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors	Number Agreed	4	4	Date Agreed	44985	7	7	31/12/2021	Recruitment finished	
47	13/YH/0317	141843	Vercise DBS Registry / version AB	Range Agreed	1	10	Date Agreed	31/12/2021	9	9	31/12/2021	Recruitment finished	
48	18/NE/0023	230930	Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D) in adults	Range Agreed	20	204	Date Agreed	31/05/2021	203	203	31/05/2021	Recruitment finished	
49	19/NE/0357	271261	A Phase 3, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) The ARMOR Study	Range Agreed	1	5	Date Agreed	44561	1	1	44545	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
50	18/LO/0122	238790	A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)	Range Agreed	4	8	Date Agreed	18/12/2021	3	3	12/11/2021	Recruitment finished	Recruitment finished early nationally as global recruitment was met
51	19/NE/0328	270912	M19-164: A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to risankizumab.	Number Agreed	5	5	Date Agreed	31/10/2021	0	0	28/08/2021	Recruitment finished	The research team were unable to find people who met the strict eligibilty criteria
52	20/LO/0453	1003010	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA	Range Agreed	3	6	Date Agreed	30/11/2021	1	1	23/06/2021	Recruitment finished	Due to competitive recruitment the team did not meet their target
53	20/HRA/4788	288786	A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19	Range Agreed	11	18	Date Agreed	44477	5	5	01/10/2021	Recruitment finished	The study closed early nationally
54	19/NW/0555	269550	A Multicenter, non-interventional, prospective study to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis in daily practice (CIMREAL)	Range Agreed	2	5	Date Agreed	17/12/2021	2	2	17/12/2021	Recruitment finished	
55	20/NE/0058	275056	A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)	Range Agreed	1	3	Date Agreed	30/06/2023	3	03/01/1900	44516	Recruitment finished	
56	18/SW/0130	246372	Prospective Evaluation of Thin-strut Biodegradable Polymer-coated Supraflex Sirolimus-Eluting Stents in an All-comers Patient Population (S-FLEX UK-II)	Range Agreed	50	100	Date Agreed	44469	73	13/03/1900	44469	Recruitment finished	
57	20/HRA/5234	290965	A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19	Number Agreed	10	10	Date Agreed	44531	10	10/01/1900	44511	Recruitment finished	
58	20/LO/0676	273137	Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)	Range Agreed	1	3	Date Agreed	44561	0	00/01/1900	44530	Recruitment finished	Recruitment finished early nationally as global recruitment was met
59	20/LO/0731	279972	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis	Range Agreed	1	3	Date Agreed	44530	1	01/01/1900	44530	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
60	19/NE/0310	263546	A Phase IIb double-blind, randomised, placebo-controlled, multi-centre, confirmative three-way cross-over study on cognitive function with two doses of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation	Range Agreed	6	10	Date Agreed	31/12/2021	6	06/01/1900	44561	Recruitment finished	
61	20/LO/0963	281310	Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)	Number Agreed	6	6	Date Agreed	31/12/2021	0	0	31/12/2021	Recruitment finished	When the study opened the team were running with 2 consultants. Unfortunately one consultant became absent due to ill health throughout the study and the team were unable to screen patients due to these circumstances
62	20/LO/0181	275690	A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma	Range Agreed	2	4	Date Agreed	44500	3	3	44500	Recruitment finished	
63	21/YH/0071	295903	Phase 2/3, Placebo-Controlled, Randomized, Observer-Blinded, Study to Evaluate to the Safety, Tolerability and Immunogenicity of SARS-CoV-2 RNA Vaccine Candidate (BNT162b2) against COVID-19 IN Healthy Pregnant Women 18 years of Age and Older.	Range Agreed	1	3	Date Agreed	44500	1	1	44494	Recruitment finished	
64	19/SC/0599	270649	A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumours	Number Agreed	5	5	Date Agreed	15/12/2023	0	0	44536	Recruitment finished	Global recruitment finished early. The team at Newcastle were only offered one slot by sponsor and the patient screen failed
65	21/NS/0037	292756	A prospective observational study to evaluate the clinical outcomes and burden of disease of PD patients with motor fluctuations not adequately controlled by current PD medications.	Number Agreed	10	10	Date Agreed	44561	7	7	44543	Recruitment finished	This study was difficult to recruit to as one of the main issues were visits coincided with normal outpatient visits and, visit windows were often cancelled because of COVID
66	21/NW/0260	299431	A Multicenter Retrospective Study of the HARMONIC Focus (+) Shears in Adult Urologic and Gynecologic Procedures and Pediatric Procedures	Number Agreed	100	100	Date Agreed	28/02/2022	103	103	44501	Recruitment finished	
67	19/LO/0043	255663	A long-term extension trial of the Phase III lipid-lowering trials to assess the effect of long-term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C	Number Agreed	3	3	Date Agreed	01/11/2021	3	3	01/11/2021	Recruitment finished	